Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Total Current Liabilities (2016 - 2025)

Anaptysbio (ANAB) has disclosed Total Current Liabilities for 10 consecutive years, with $38.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Current Liabilities fell 14.98% year-over-year to $38.6 million, compared with a TTM value of $38.6 million through Dec 2025, down 14.98%, and an annual FY2025 reading of $38.6 million, down 14.98% over the prior year.
  • Total Current Liabilities was $38.6 million for Q4 2025 at Anaptysbio, up from $38.1 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $45.4 million in Q4 2024 and bottomed at $16.1 million in Q4 2021.
  • Average Total Current Liabilities over 5 years is $31.8 million, with a median of $35.8 million recorded in 2023.
  • The sharpest move saw Total Current Liabilities dropped 18.78% in 2021, then soared 86.0% in 2023.
  • Year by year, Total Current Liabilities stood at $16.1 million in 2021, then skyrocketed by 61.84% to $26.1 million in 2022, then skyrocketed by 43.71% to $37.4 million in 2023, then rose by 21.33% to $45.4 million in 2024, then decreased by 14.98% to $38.6 million in 2025.
  • Business Quant data shows Total Current Liabilities for ANAB at $38.6 million in Q4 2025, $38.1 million in Q3 2025, and $44.0 million in Q1 2025.